Multicompartment Hard Capsule with Control Release Properties by Digenis, George & Noskova, Dagmar
University of Kentucky
UKnowledge
Pharmaceutical Sciences Faculty Patents Pharmaceutical Sciences
9-30-1997
Multicompartment Hard Capsule with Control
Release Properties
George Digenis
University of Kentucky, digenis@uky.edu
Dagmar Noskova
University of Kentucky
Right click to open a feedback form in a new tab to let us know how this document benefits you.
Follow this and additional works at: https://uknowledge.uky.edu/ps_patents
Part of the Pharmacy and Pharmaceutical Sciences Commons
This Patent is brought to you for free and open access by the Pharmaceutical Sciences at UKnowledge. It has been accepted for inclusion in
Pharmaceutical Sciences Faculty Patents by an authorized administrator of UKnowledge. For more information, please contact
UKnowledge@lsv.uky.edu.
Recommended Citation
Digenis, George and Noskova, Dagmar, "Multicompartment Hard Capsule with Control Release Properties" (1997). Pharmaceutical
Sciences Faculty Patents. 89.
https://uknowledge.uky.edu/ps_patents/89
United States Patent [191 
Digenis et al. ' 
[11] Patent Number: 5,672,359 
[45] Date of Patent: Sep. 30, 1997 
[54] MULTICOMPARTMENT HARD CAPSULE 
WITH CONTROL RELEASE PROPERTIES 
[75] Inventors: George A. Digenis; Dagmar Noskova, 
both of,Lexingt0n, Ky. 
[73] Assignee: The University of Kentucky Research 
Foundation, Lexington, Ky. 
[21] Appl. No.1 560,946 
[22] Filed: Nov. 20, 1995 
Related U.S. Application Data 
[63] Continuation of Ser. No. 94,637, 1111.21, 1993, abandoned. 
[51] Int. 01.6 ..................................................... .. A61K 9/52 
[52] U.S. c1. ........................ .. 424/463; 424/452; 424/453; 
424/454; 424/455; 424/456; 424/408 
[58] Field of Search ................................... .. 424/408, 433, 
424/436, 438, 417, 452, 456-463, 494, 
502; 514/962, 965, 967 
[56] References Cited 
U.S. PATENT DOCUMENTS 
2,451,022 10/1948 Domrmann ........................... .. 424/408 
3,122,475 2/1964 Schaeppi ......... .. 167/64 
3,197,369 7/1965 Widmann et al. 167/64 
3,415,249 12/1968 Sperti .......... .. 167/64 
3,814,809 6/1974 Gordon 424/19 
4,707,362 11/1987 Nuwayser 828 840 5 9 Sak moto et a1. 
4,880,830 11/1989 Rhodes .... .. 
4,994,279 2/1991 Aoki et a1. 
5,023,088 6/1991 Wong et al. .. 
5,156,849 10/1992 Byrne et a1. ........ .. 
5,219,572 6/1993 Sivannak?shnan .. .... .. 424/438 
5,262,173 11/1993 Sheth et a1. . . . . . . . . . . . . . . . .. 424/494 
5,271,945 12/1993 Yoshioka et a1. . .... .. 424/489 
5,314,697 5/1994 Kwan et a1. . . . . . . . . . . .. 424/480 
5,320,853 6/1994 Noda et a1. .... .. 424/472 
5,472,708 12/1995 Chen ..................................... .. 424/451 
FOREIGN PATENT DOCUMENTS 
0274150 3/1964 Australia ............................. .. 4241463 
4157820 5/1978 Japan . 
0046826 4/1979 Japan ........................... .. 424/DIG. 15 
0073017 6/1981 Japan 424/DIG. 15 
56-73018 6/1981 Japan 424/DIG. 15 
143109 4/1976 United Kingdom . 
OTHER PUBLICATIONS 
Merck Index, Abstract 6101, Miconazole, p. 972. 
Merck Index, Abstract 139, Acyclovir, p. 24. 
Porter, S.C. “Coating of Pharmaceutical Dosage Forms”, 
Remington ’s Pharmaceutical Sciences, 18th Ed.(1990) pub 
lished by Mack Publishing Co., Easton, PA, pp. 1666-1675. 
Kraeling, M.E.K. and Ritschel, W.A. “Development of a 
Colonic Release Capsule Dosage From and the Absorption 
of Insulin”, Meth. Find. E230. Clin. Pharmacol, vol. 14, No. 
3, (1992) pp. 199-209. 
Primary Examiner-—Neil S. Levy 
Attorney, Agent, or Firm--Lowe, Price, LeBlanc & Becker 
[57] ABSTRACT 
The present invention relates to a hard capsule made from a 
material such as gelatin, starch or a hydrophilic polymer. 
The capsule of the present invention is formulated into a 
delivery system which incorporates pharmacologically 
active components in three or more distinct compartments. 
When three compartments are utilized in the capsule, the 
outer compartment incorporates a drug and excipients into a 
layer which coats the outer part of the capsule. This layer 
represents the rapid release portion of the delivery system. 
The intermediate compartment comprises a powder formu 
lation comprised of a drug and excipients which represents 
the intermediary speed release portion of the delivery sys 
tem. The innermost compartment incorporates the active 
ingredient or ingredients in a multiparticulate form, such as 
small pellets, and represents the slow release component of 
the delivery system. 
18 Claims, 4 Drawing Sheets 































O M a | l l l l | 


















l I l l Q 





MULTICOMPARTMENT HARD CAPSULE 
WITH CONTROL RELEASE PROPERTIES 
This application is a continuation of application Ser. No. 
08/094,637 ?led Jul. 21, 1993 now abandoned. 
TECHNICAL FIELD 
The present invention relates to a hard capsule which can 
deliver a desirable agent, such as a drug or an odoriferous 
agent, over a prolonged period of time. 
The invention provides a hard capsule made from gelatin, 
starch or a hydrophilic polymer, such as hydroxypropyl 
methylcellulose (HPMC) or carboxymethyl cellulose, which 
by virtue of its design and composition provides an imme 
diate and sustained mode of release of its pharmacologically 
active or otherwise desirable components in an aqueous 
environment. 
BACKGROUND AKI‘ 
Suppositories are known to be useful in the delivery of 
drugs. For example, U.S. Pat. No. 3,814,809 to Gordon et al. 
discloses a vaginal suppository composed of CARBO 
WAXTM and a medicament such as prostaglandin. 
Suppositories may be multilayered. Japanese Publication 
Nos. JP-150,421 and JP-l50,422 disclose a multi-layered 
suppository. In each layer, one or more medical components 
are mixed with one or more water-soluble base materials 
such as Macrogol. The suppository disclosed in the Abstract 
of 150,422 contains two layers and does not contain an outer 
coating layer. 
Japanese Application 065289 discloses a two-layered 
suppository comprising successively charged molten water 
soluble bases (Macrogol or glycerogelatin). The suppository 
includes a water-soluble base layer in the lower half of the 
suppository and a fat-soluble base layer in the upper half. 
The suppositories are both rapid and long-acting. This 
suppository does not include an outer coating layer which 
includes a drug to provide immediate drug release. 
Japanese Application 102,055 discloses a slow-release 
rectal suppository which is the product of connecting a 
suppository prepared with a water-soluble base material and 
a suppository prepared with a water-soluble base material 
and surface coated with a base material which is insoluble in 
water and which does not melt quickly at rectal tempera 
tures. The water-soluble base material may be a mixture of 
gelatin and glycerine or a mixture of two or more Macrogol. 
The coated suppository is a slow-releasing rectal supposi 
tory and does not include an outer coating layer which 
includes a drug to provide immediate drug release. 
UK Patent 1,431,092 discloses that certain types of sup 
positories have thin protective coatings, which may also 
contain medicarnents or the like are, and which are some 
times used to reduce premature melting. This outer coating 
appears to teach away from the use of a fast releasing outer 
coating which contains a drug. 
U.S. Pat. No. 3,197,369 to Widman et al. discloses coated 
gelatin capsules. The coating of the gelatin capsule does not 
contain a medicament for immediate drug release. 
U.S. Pat. No. 3,122,475 to Schaeppi discloses a multi 
layer suppository containing sequentially acting medica 
ments e?iective for treating heart decompensation. In this 
suppository, the core represents about one-?fth to one-third 
of the total weight of the suppository and the shell represents 
?re remaining four-?fth to two-thirds. The suppository core 










para?inic wax. The suppository shell can be composed of 
the same ingredients and melts at 37° to 38° C. 
U.S. Pat. No. 3,415,249 to Sperti discloses a suppository 
comprising a ?rst and second body. The ?rst body consists 
of a suppository base and a coating. The base may be a 
polyethylene glycol and the coating may also be a polyeth 
ylene glycol. Sperti also discloses that the base of the 
coating should have a substantially lower melting point than 
the base of the suppository. Sperti discloses that it is possible 
to locate a thin barrier layer over the body of the suppository 
prior to the application of the coating. Such an additional 
layer may be of moisturized gelatin. The coating can contain 
an anesthetic substance and the body of the suppository 
contains a medicament such as an agent for the stimulation 
of cellular respiration. ‘The thin barrier layer does not contain 
a medicament. 
U.S. Pat. No. 4,707,362 to Nuwayser discloses a vehicle 
for providing both rapid release and prolonged release of a 
drug. The vehicle may be a vaginal suppository. The sup 
pository body melts at body temperature and includes a 
bioerodible ?lm insert. The suppository may contain a 
spermicide such as Nonoxynol-9. The suppository does not 
include three compartments for differential drug release. 
U.S. Pat. No. 4,880,830 to Rhodes discloses a slow 
release formulation for the preparation of tablets, capsules, 
suppositories or implants (see column 2, line 59) which 
comprises granules which are composed of particles com 
prising an inactive ingredient and a primary matrix of 
water-soluble slow release material in which are dispersed 
particles comprising an active ingredient. The formulation 
also contains a secondary matrix of water-soluble dispers 
ible slow release material in which the granules of medica 
ment are dispersed. At least one of the matrices may be 
gelatin. The suppository can contain secondary granules 
which are of a larger size than primary granules, and if 
desired tablets or capsules may be enteric ?lm or sugar 
coated. Rhodes does not disclose a fast releasing outer 
coating containing a medicament. 
U.S. Pat. No. 4,828,840 to Sakamoto et al. discloses a 
sustained released formulation of a water-soluble active 
ingredient comprising an inert core, a powder coating layer 
surrounding the core, a second powder coating layer sur 
rounding the ?rst powder coating layer, and a ?lm coating 
layer surrounding the second powder coating layer. The ?lm 
coating layers include polyvinylpyrrolidone, hydroxypropyl 
methylcellulose and starches. The ?lm coating layer does 
not contain a medicament. 
An example of a controlled release product which is 
commercially available is the product PROCARDIA XLTM 
distributed by P?zer (1235 East 42nd St., New York, N.Y.). 
This is an extended release tablet which is designed to 
provide the cardiovascular drug nifedipine at an approxi 
mate constant rate over 24 hours (PDR 47th Ed 1993, 
Medical Economics Data). In PROCARDIA XLTM the tablet 
depends for its action on the existence of an osmotic gradient 
between the contents of its bilayer core and the ?uid in the 
GI tract. Drug delivery is essentially constant as long as the 
osmotic gradient remains constant, and then it gradually 
falls to zero. Upon swallowing, the biologically inert com 
ponents of the tablet remain intact during GI transit and are 
eliminated in the feces as an insoluble shell. The osmotic 
gradient in this tablet is achieved by the introduction of a 
semipermeable membrane surrounding an osmotically 
active drug core. The core is divided into two layers: an 
“active” layer containing the drug, and a “push” layer 
containing pharmacologically inter (but osmotically active) 
5,672,359 
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components. As water from the gastrointestinal tract enters 
the tablet, pressure increases in the osmotic layer and 
“pushes” against the drug layer, releasing the drug through 
a precision laser drilled tablet ori?ce in the active layer. 
There is a need in the medical and pharmaceutical disci 
plines for a drug delivery system which incorporates phar 
rnacologically active components in three or more di?eren 
tially releasing drug compartments. This need particularly 
exists in vaginal applications wherein the release of the drug 
has to begin shortly after administration such as in the case 
of a spermicide or an anti-HIV agent and in which the drug 
release must conn'nue for several hours to achieve the 
desired sperrnicidal and anti-HIV result. 
The drug delivery system of the present invention pro 
vides a capsule of differentially releasing distinct compart 
ments. The outer compartment provides a rapid release of a 
drug incorporated into the outer compartment. An interme 
diate compartment provides an intermediary speed release 
portion of the delivery system. And the innermost compart 
ment provides a slow release component of the delivery 
system. The drug delivery system overcomes inadequacies 
of prior capsule formulations to provide controlled imme 
diate and prolonged release of a desired agent in an aqueous 
environment. 
DISCLOSURE OF THE INVENTION 
The present invention provides a hard capsule drug deliv 
ery system comprising at least one inner compartment, at 
least one intermediate compartment surrounding the at least 
one inner compartment and at least one outer compartment 
surroundingthe at least one intermediate compartment, and 
wherein each compartment comprises at least one drug 
component. 
The present invention provides a drug delivery system of 
a hard capsule comprising an outer compartment, an inter 
mediate compartment and an inner compartment, wherein 
the rate of release of the drug component of the outer 
compartment is faster than the rate of release of the inter 
mediate compartment, and the rate of release of the inter 
mediate compartrnent is faster than the rate of release of the 
inner compartment. 
In a further embodiment, the invention provides a hard 
capsule drug delivery system comprising at least one inner 
compartment, at least one intermediate compartment sur 
rounding the at least one inner compartment and at least one 
outer compartment surrounding the at least one intermediate 
compartment, and wherein each compartment comprises at 
least one drug component, wherein the outer compartment 
begins release of the drug component about 1 minute after 
immersion of the hard capsule into an aqueous medium and 
completes release of the drug component about 45 to 50 
minutes after immersion of the capsule into an aqueous 
medium 
A still further embodiment of the invention provides a 
method for manufacturing a drug delivery system compris 
ing the steps of forming a capsule comprising at least one 
inner compartment; 
surrounding the inner compartment with at least one 
intermediate compartment; and 
surrounding the intermediate compartment with at least 
one outer compartment, wherein each compartment 
comprises at least one drug component and wherein the 
outer component comprises a mixture of the drug 
component and an excipient coating the intermediate 
compartment. ' 
An additional embodiment of the invention provides 










partment of the capsule from 45 to 50 minutes after immer 
‘sion of the capsule into an aqueous medium; release of the 
drug or active agent from the intermediate compartment 
occurs from 10 min. to 1.5 hours after immersion of the 
capsule in a liquid medium and the release of the drug from 
the intermediate compartment is completed from 4 to 5 
hours after immersion of the capsule in a liquid medium. The 
initial release of the drug or active agent from an inner 
compartment of the drug delivery system occurs from about 
1 to 2 hours after irmnersion of the capsule in a liquid 
medium and the release of the drug from an inner compart 
ment is completed from about 7 to 8 hours after immersion 
of the capsule in a liquid medium. 
The invention also provides a drug delivery system useful 
in vaginal applications wherein the release of the drug 
begins shortly after administration such as in the case of a 
spermicide or an anti-HIV agent and in which the drug 
release must continue for several hours to achieve the 
desired sperrnicidal and. anti-HIV result. 
The capsule of invention provides an ideal vehicle for 
colonic drug delivery of peptide drugs and an inexpensive 
method for drug delivery to the gastrointestinal tract. 
The multicompartment coated capsule of the invention, in 
an additional embodiment comprises a “One a Day” single 
dosage control release capsule. 
Other objects, features, aspects and advantages of the 
invention will be more apparent to those of skill in the 
dispensing art from the following detailed speci?cation 
taken in conjunction with the drawing ?gures and the 
accompanying claims. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shows a perspective view of the capsule of the 
present invention. 
FIG. 2 shows a chart indicating the rate of release of an 
active component measured by the rate of iodine release 
from the outer compartment of the capsule. 
FIG. 3 shows a chart indicating the rate of release from the 
middle compartment of a hard capsule packed with 170 mg 
of PVP-I/N-9 and 170 mg of Ac-Di-Sol. 
FIG. 4 shows a chart indicating the rate of release ?'om the 
inner compartment of a hard capsule packed with ?ve 
PCP-I/N-9 pellets dispersed into a powder containing 170 
mg of PVP and 170 mg of AC-DI-SOL. The term AC-TI 
SOL used throughout the speci?cation means crosscarmel 
lose sodium. “W/W" means “weight %” as used throughout 
the speci?cation. 
DESCRIPTION OF THE INVENTION 
The present invention relates to a hard capsule formulated 
into a delivery system which incorporates pharmacologi 
cally active components in three or more distinct compart 
ments. 
The capsule includes at least one inner compartment, at 
least one intermediate compartment surrounding the at least 
one inner compartment and at least one outer compartment 
surrounding the at least one intermediate compartment, and 
each compartment comprises at least one drug component or 
active agent. 
Preferably in the hard capsule the rate of release of the 
drug component of the outer compartment is faster than the 
rate of release of the intermediate compartment, and the rate 
of release of the intermediate compartment is faster than the 
rate of release of the inner compartment. 
The capsule may be made from gelatin, starch, hydrox 




When three compartments are utilized in the capsule, the 
outer compartment may incorporate a drug, active agent or 
odoriferous agent and excipients into a layer which coats 
and thus surrounds the intermediate component of the cap 
sule. This outer component represents the rapid release 
portion of the delivery system. The intermediate compart 
ment comprises a powder formulation which represents the 
intermediate rate of release portion of the delivery system. 
The innermost compartment incorporates the active ingre 
dient or ingredients in a multiparticulate form, such as small 
pellets which may be coated or uncoated, and represents the 
slow release compartment of the delivery system. 
Thus the drug delivery system of the invention possesses 
the ability to deliver a desired drug or combination of drugs 
from a period of time ranging from seconds after adminis 
tration to several hours. 
The rate of release of the drugs from a capsule consisting 
of three or more compartments may be controlled. An 
alteration in its composition as well as in the temperature 
will result in the changed release pro?le. The optimal ratio 
of drug to excipient in the outer compartment may be 
adjusted based on the drug properties and the required 
coating extent of the outer surface of the capsule according 
to methods known in the art. The release of the drug or drugs 
from the outer compartment of the capsule can begin as 
quickly as about one minute after the capsule’s immersion 
into an aqueous medium, and a complete release of the drug 
in the outer compartment can occur within a period of 45 to 
50 minutes after immersion. 
The intermediate compartment may contain up to 300 mg 
of a drug powder in an O-size capsule. Although a O-size 
capsule is preferred, any size capsule may be used. Capsule 
size is directly related to the method of administration of the 
capsule. Larger capsules may be hard to swallow. If the 
capsule is for gastrointestinal administration O-size, OO-size 
or OOO-size capsules are preferred. Larger capsules may be 
used for vaginal or rectal administration. 
Release of the drug ?om the intermediate or middle 
compartment may begin at approximately one hour after 
immersion of the capsule in an aqueous medium, and release 
may be completed within 4 to 5 hours after administration an 
immersion in an aqueous medium. The intermediate com 
partrnent comprises a powder drug component or active 
agent. The release time of the drug from this compartment 
could be changed by an appropriate alteration in its formu 
lation. 
The drug component or active agent contained in an inner 
compartment of the capsule is preferably a pellet formula 
tion. The inner compartment consists of one or more pellets 
which may be coated or uncoated. The coating solution for 
the pellet is adapted for sustained release in the gastrointes 
?nal tract and may contain mixtures of waxes with glycerol 
monostearate, stearic acid, palmitic acid, shellac and zein 
polymers, ethylcellulose acrylic resins and other materials as 
outlined in Remington ’s Phamtaceutical Sciences. The rate 
of release of the drug from the inner compartment is a 
function of the rate of disintegration of the hard capsule wall 
and that of the pellets. The size of the pellet may be adjusted 
in accordance with the amount of drug to be delivered and 
the desired rate of drug release. For example, the pellets may 
range in size from about 1 mm to about 3 mm in diameter. 
The release of the drug from an inner compartment is 
completed from about 7 to 8 hours after immersion of the 
capsule in a liquid medium. 
The drug delivery system is particularly useful in vaginal 











agent has to begin shortly after administration such as in the 
case of a spermicide or an anti-I-HV agent and in which the 
drug release must continue for several hours to achieve the 
desired spermicidal and anti-HIV result 
Applications of the drug delivery system include, but are 
not limited to the delivery of drugs for the treatment of 
vaginal yeast infections and for rectal use for the delivery of 
hemorrhoidal drugs. The capsules may contain odoriferous 
agents for vaginal or other delivery. The drug delivery 
system according to the present invention may also ?nd 
internal use for controlled release delivery of drugs or 
vitamin nutritional supplements, or any other bene?cial 
agent. The capsule is preferably used in the delivery of 
peptide drugs to the colon. 
The outer compartment or coating preferably contains a 
drug component or active agent and an excipient compo 
nent. In one embodiment of the drug delivery system the 
drug component or active agent and the excipient compo 
nent are solubilized in alcohol, such as methanol or ethanol. 
Preferably the concentration of the drug component or active 
agent is 8% to 50% w/v. The excipient component may 
include CARBOWAXTM 8,000, CARBOWAXTM 4,600, 
CARBOWAXTM3350 or CARBOWAXTM 1,450, hydrox 
ypropyl methylcellulose (HPMC) or mixtures thereof. CAR 
BOWAXTM is a trademark of Union Carbide for polyethyl 
ene glycol polymers. 
Additionally, when the above solid components are solu 
bilized in water, methanol or ethanol, they form a dipping 
solution or spray coating, the composition of which ranges 
from about 10%:0%:8% to about 12.5%:10%:50% of 
Carbowaxesm, hydroxypropyl methylcellulose and drug, 
respectively. A preferred method for constructing the outer, 
rapid release compartment of the delivery system consists of 
an appropriate mixing of the desired drug with polyethylene 
glycol CARBOWAXTM 8,000; 4,600; 3,350; and 1,450 or a 
mixture of CARBOWAXTM, HPMC and the drug. The hard 
capsule can be dipped several times or spray coated until the 
appropriate outer compartment is formed. This procedure 
may be utilized to coat hard capsules made from gelatin, 
starch or a hydrophilic polymer such as HPMC. 
If the drug component or active agent does not include a 
derivative of polyvinylpyrrolidone (PVP) as an active ingre 
dient (such as PVP-I), the excipient used in the capsule may 
comprise polyvinylpyrrolidone. Preferably the concentra 
tion of the excipient component is 10% to 12.5% w/v, and 
alternatively the concentration of the excipient is 0% to 10% 
WW. When the above solid components are solubilized in 
water, methanol or ethanol, they form a coating solution. 
The composition of the coating solution preferably ranges 
from 10%-12.5% CARBOWAXTM, from 0%—l0% HPMC, 
and from 8%—50% drug. 
According to the present invention, the drug delivery 
system includes an intermediate compartment comprised of 
a drug component or active agent and a disintegrant com 
ponent. The disintegrant component may comprise from 100 
mg to 180 mg of Ac-Si-SolTM, which is a modi?ed cellulose 
gum which is an internally crosslinked form of a sodium salt 
of carboxymethyl cellulose of USP pm-ity. The disintegrant 
absorbs water and swells and thus contributes to the collapse 
of the capsule wall, upon which the contents of the capsule 
are delivered. The proportion of the disintegrant to the drug 
determines the time of release of the capsule contents in to 
tie surrounding medium. 
In a preferred embodiment the concentration of the drug 
component or active agent in the intermediate compartment 
ranges from about 125 to about 170 mg. 
5,672,359 
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The inner compartment may also be comprised of a drug 
component or active agent and an excipient component. 
Preferably the excipient of the inner compartment is selected 
from lactose, magnesium stearate, Ac-Di-Sol, or calcium 
phosphate, or mixtures thereof. The inner compartment of 
the drug delivery system according to the invention 
includes, in a preferred embodiment, a pellet formulation 
comprises from 7% to 70% w/w drug component or active 
agent, from 10% to 84% w/w lactose, and from 6% to 20% 
w/w magnesium stearate. The pellets are compressed using 
pressure of 600-1000 pounds. 
The inner compartment of the drug delivery system of the 
present invention is comprised of the desired drug formu 
lated in a multiparticulate form. For example, pellets weigh 
ing 30 mg each (approximately 3 mm in diameter) can be 
dispersed into the inner compartment of the hard capsule. 
The pellets contain the drug and several excipients which 
determine their physical characteristics and their rate of 
dissolution in an aqueous medium ' 
Also contemplated within the scope of the present inven 
tion is a drug delivery system comprising a hard capsule 
with differential rates of release of the drug component or 
active agent as outlined below. ‘The drug is preferably 
completely released from the outer compartment from 45 to 
50 minutes after irmnersion of the capsule into an aqueous 
medium, the release of the drug from the intermediate 
compartment, for example, occurs from 10 min. to 1.5 hours 
after immersion of the capsule in a liquid medium and the 
release of the drug from the intermediate compartment is 
completed from 4 to 5 hours after immersion of the capsule 
in a liquid medium. The initial release of the drug from an 
inner compartment of the drug delivery system occurs from 
about 1 to 2 hours after immersion of the capsule in a liquid 
medium and the release of the drug from an inner compart 
ment is completed from about 7 to 8 hours after immersion 
of the capsule in a liquid medium. 
A preferred method for manufacturing a drug delivery 
system according to the invention includes the steps of 
forming a capsule comprising at least one inner compart 
ment; surrounding the inner compartment with at least one 
intermediate compartment; and surrounding the intermedi 
ate comparunent with at least one outer compartment, with 
each compartment comprising at least one drug component 
or active agent and wherein the outer component comprises 
a mixture of the drug component or active agent and an 
excipient coating the intermediate compartment. 
Coating of the capsule wall which surrounds the interme 
diate compartment may be accomplished by dipping the 
capsule in the mixture of drug and excipient. Coating may 
also be accomplished by spray coating the capsule with the 
mixture of drug and excipient. Conventional dipping and 
coating procedures are known and acceptable for the prac 
tice of the present invention and are outlined in Remington ’s 
Pharmaceutical Sciences, 18th Ed. (1990) published by 
Mack Publishing Co., Easton, Pa., p. 1666-1675 and are 
incorporated herein by reference. 
Drugs to be administered in the drug delivery device 
according to the present invention may be administered in 
accordance with daily dosages known in the art and as 
outlined in Remington ’s Pharmaceutical Sciences, 18th Ed. 
(1990) published by Mack Publishing Co., Easton, Pa. 
Examples of drugs to be delivered vaginally include but 
are not limited to spermicides such as Nonoxynol-9 
(nonylphenoxypolyethoxy-ethanol), Octoxynol (diisobutyl 
phenoxypolyethanol), p-methanylphenyl polyoxyethylene, 







fate. Nonoxynol-9 is preferred. Vaginal drugs such as 
miconazole, acyclovir, clotrimazole, ticonizole, hormones 
such as estrogens; metronidazole, sulfas including 
sulfabenzamide, sulfacetarnide, sulfacytine, sulfatrizaole; 
tetracycline hydrochloride, erythromycin, achromycin, 
chloromycetin, penicillin, chlortetracycline bacitracin, and 
nystatin may be administered in the drug delivery system 
according to the present invention. Anti-in?ammatory 
agents such as aspirin, chlocortolone pivalate, 
hydrocortisone, tolmetin sodium, and indomethacin may 
also be administered. The drug delivery system is also useful 
in the delivery of germicides, such as benzalkonium and 
chlorhexidine and virucides, such as anti-HIV drugs. 
The solubility of the drug in the coating solvent does 
create a limitation on the practice of the invention. The 
coating procedure can be practiced with a highly soluble 
drug as well as a completely insoluble drug component or 
active agent by coating the capsule with a coating suspen 
sion as set forth in example 6. 
In a preferred embodiment, the capsule of the invention is 
used for the colonic delivery of peptide drugs. Certain 
peptide drugs can be delivered from the colon if they are 
protected from proteolytic destruction in the particular site 
of the gastrointestinal tract (GI). 
Absorption enhancers may be used to facilitate the 
absorption of these relatively large peptide molecules. Con 
sequently to achieve drug absorption of these peptides, the 
drug formulation preferably contains a protease (proteolytic 
enzyme) inhibitor and one or more absorption enhancers. 
See M. E. K Kraeling and W. A. Ritschel, “Development of 
Colonic Release Capsule Dosage Form and the Absorption 
of Insulin”, Meth. Find. Exp. Clin. Pharmacol. (1992), Vol. 
14(3), pp. 199-209, incorporated herein by reference. 
In one embodiment the multicompartrnent capsule of the 
present invention permits the release of the absorption 
enhancer(s) and the protease inhibitor prior to the release of 
the peptide drug. This offers the advantage that the mem 
brane of the colon is predisposed to permit the crossing of 
the peptide drug and thus -the colon would be free of 
proteolytic activity at the time the drug is released from the 
capsule. 
In this embodiment, the protease inhibitor and the absorp 
tion enhancers could either be present in the outer compart 
ment or the outer and intermediate compartments of the 
multicompartment capsule. The peptide drug may be intro 
duced in the intermediate compartment and the inner slow 
releasing compartment of the capsule. Alternately, the pep 
tide drug may be introduced in only the pelletized inner 
compartment of the multicompartment capsule. 
To achieve colonic delivery of the capsule contents, the 
capsules are coated with such polymer coatings as Eudragit 
NE 30, Eudragit S100, cellulose acetate phthalate (CAP), 
cellulose acetate succinate (CAS), cellulose acetate trimel 
litate (CAT) or cellulose acetate butyrate (CAB). The above 
polymers are acid resistant and dissipate from the surface of 
the capsule via pH-dependent and time controlled release 
mechanisms known in the art. 
Examples of peptide drugs which may be used in the 
capsule of the present invention include insulin, calcitonin, 
interferon, interleukins and proteins in oral vaccines. 
Examples of absorption enhancers are fatty acids, bile salts 
such as sodium taurocholate, caprylate myristate, glycerides, 
such as phosphatidyl choline, lecitins, salicylates and lauryl 
sulfate. Examples of protease inhibitors for use in this 
embodiment of the invention, include but are not limited to 




In a further advantageous embodiment of the invention, 
the multicompartrnent capsule can be used in the design of 
oral drug delivery dosage forms generally referred to as “one 
a day” formulations. These formulations are particularly 
useful in drug delivery to the elderly. 
Compliance in dosage regimen is often di?icult to 
achieve, particularly among the elderly. It is therefore 
desirable, in the case of several drugs, to take one pill or 
dosage form per day (“one a day”). To achieve this regimen 
the dosage form has to be a delivery system that can 
continuously deliver the drug in a controlled release manner. 
The delivery of the drug from the multicompartment 
capsule of the invention, in a preferred embodiment, is 
continuous when the drug is appropriately distributed in 
each of the capsule compartments. The capsule of the 
invention is much easier to produce and thus more cost 
eifective than the commercially available PROCARDIA 
XLTM tablet. In addition, the multicompartment capsule 
dissipates completely prior to its elimination from the body 
of a patient while the PROCARDIA XLTM tablet is elimi 
nated in the feces intact, as an insoluble shell. This insoluble 
tablet has the potential to provide complications to some 
patients. 
Odoriferous agents which may be administered in the 
capsule according to the invention, include but are not 
limited to aromatic substances, fragrances, and absorbents. 
Examples of fragrances which may be included in the 
capsule are linalol and geraniol and etherial oils such as 
lemon oil and lavender oil. In a preferred embodiment, the 
capsule contains 10% citronella oil in admixture with olive 
oil, as a fragrance extender and enhancer. 
In addition to the foregoing critical components, various 
optional ingredients as a conventionally used in the art, may 
be employed. These optional ingredients include, for 
example, ?avorings, colorings, sweeteners, fragrances, 
diluents, ?llers, preservatives, antioxidants, stabilizers, and 
lubricants. 
In an alternative embodiment, the drug delivery system of 
the invention can be fabricated into any convenient shape for 
insertion into a body cavity or for administration via the 
gastrointestinal tract to meet a wide variety of functional 
requirements. Shaping can be affected, for example, by 
injection molding, compression molding, hot dipping, 
extrusion, melt casting and similar techniques. 
Reference will now be made in detail to the ?gures 
including preferred embodiments and methods of the present 
invention. 
FIG. 1 illustrates a hard capsule 10 which is formed from 
gelatin, starch or hydrophilic polymer, and which comprises 
a three compartment delivery system for its pharmacologi 
cally active components. The outer compartment 12 incor 
porates a drug and excipients into a layer which coats the 
outer part of the capsule. This outer compartment represents 
the rapid release portion of the capsule. The intermediate 
compartment 11 contains a powder formulation 13 which is 
introduced into the hard capsule 10 and provides an 
intermediate-speed release portion of the capsule. The inner 
compartment of the capsule contains active ingredients 
which are in the form of small pellets 14 and which release 
their drug component or active agent more slowly than that 
of the outer or intermediate compartments. 
FIG. 2 illustrates the pro?le of the rate of release of 
PVP-IIN-9, which possesses spermicidal and anti-HIV prop 
erties at pH 5.0, from the outer compartment determined 
spectrophotometrically measuring the release of iodine into 











gelatin capsule with an outer layer of an active component 
and an excipient was placed into 10 mL of water at pH 5.0 
and stirred at 24° C. 
As can be seen from FIG. 2, the release of the active 
ingredients, as measured by the rate of release of iodine, 
from the outer compartment of the capsule begins at 
approximately one minute after immersion into an aqueous 
medium. Complete release of the PVP-I/N-9 from the outer 
compartment of the capsule is attained within 45-50 minutes 
after immersion of the capsule into the aqueous medium. 
FIG. 3 illustrates the pro?le of the rate of release of 
PVP-I/N-9 from the middle or intermediate compartment, 
determined by spectrophotometrically measuring the release 
of iodine into the medium, into water at pH 5.0 stirred at 24° 
C. In the embodiment illustrated by FIG. 3, the rate of 
release of drug from the intermediate compartment of the 
capsule is slower than the rate of release of drug from the 
outer compartment as illustrated in FIG. 2. 
FIG. 3 further illustrates that the release of the drug from 
the intermediate compartment begins approximately one 
hour after immersion of the capsule into the aqueous 
medium, and attains a complete release Within 4 to 5 hours. 
FIG. 4 illustrates the pro?le of the release of the drug 
PVP-I/N-9 from the inner compartment, measured spectro 
photometrically by following the release of iodine into the 
medium, in this case water with a pH of about 5.0. In the 
example illustrated by FIG. 4, a hard size-0 capsule was 
packed with about 170 mg of PVP, 170 mg of Ac-Di-Sol and 
?ve pellets, each pellet being compressed under 600 to 1000 
pounds of pressure from the mixture of 70% PVP-I/N-9, 
15% calcium phosphate or lactose, 15% magnesium stearate 
and 0% Ac-Di-Sol. As can be seen from FIG. 4, the rate of 
release of PVP-I/N-9 from the inner compartment is slower 
than the rate of release from the intermediate compartment, 
as illustrated in FIG. 3, and the rate of release from the outer 
compartment, as illustrated by FIG. 2. 
While not intending to limit the scope of the invention in 
any manner, the following examples are given to illustrate 
various potential embodiments of the present invention. 
EXAMPLE 1 
The various coating solutions form the creation of the 
outer compartment are made according to the following 
general procedure: Stock solutions of 30%-50% w/v of 
CARBOWAXTM 8,000, 4,600, 3,350, or 1,450, 0%-30% 
w/v hydroxypropyl methylcellulose (HPMC) and 
24%-66.7% w/v are made in water or alcohol. 
The appropriate amount of CARBOWAXTM stock solu 
tion is mixed with aliquots of HPMC and PVP-I/N-9 stock 
solutions in order to obtain the coating solution composition 
which ranges from 10% to 12.5% wlv of CARBOWAX, 0% 
to 10% w/v of HPMC and 8% to 50% w/v of PV'P-Im-9. 
Subsequently, the hard gelatin capsule, size 0, is repeat 
edly coated by the coating solution depending upon the 
amount of solution desired for the outer compartment and 
dried until a su?icient outer compartment is formed. The 
extent of coating of the outer layer on a O-size hard gelatin 
capsule ranges from about 10 to 80 mg. The amount of the 
drug in this outer compartment ranges from about 3 to 64 
mg. 
EXAMPLE 2 
A coating solution containing the anti-HIV drug, 3-azido 
3-deoxythymidine (AZT) as the active component is made 
according to the general procedure described in Example 1; 
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1 mL of 50% w/v stock solution of CARBOWAXTM 1,450 
is mixed with 3 mL of 20% w/v stock solution of AZT, 
producing the solution of CARBOWAXTM 1,450 andAZT in 
a l2.5%/26.7% w/v ratio. The hard gelatin or starch capsule, 
size 0, is coated by the coating solution and then dried. The 
extent of the coating of the outer compartment on a O-sized 
starch capsule ranges from about 20 to 30 mg. The amount 
of AZT in this outer layer ranges from about 12 to 18 mg. 
EXAMPLE 3 
A coating solution was made from a coprecipitate of 
nonoxynol-9, polyvinyl pyrrolidone and iodine (PVP-I/N 
9), sperrnicidal with anti-HIV properties, and CARBO 
WAXTM 1,450 in the ratio of 50%/12% w/v. The solution 
successfully coated a O-size gelatin or starch capsule. The 
extent of coating of the outer surface of a O-size gelatin or 
starch capsule by the above described method ranged from 
10 to 80 mg. This amount of coating includes the active 
component, in this case PVP-I/N-9, and the excipient, such 
as CARBOWAXTM. The amount of the drug in the outer 
layer ranged from 3 to 64 mg. The optimal ratio of drug to 
excipients in the coating solution may be adjusted according 
to the properties of the drug and the required extent of 
coating in the outer layer of the capsule. 
EXAMPLE4 
A coating suspension containing the antifungal drug 
miconazole nitrate, 1-[2,4-Dichloro-B-(2,4-dichlorobenzyl) 
oxy]-phenethyl-imidazole mononitrate (MONISI‘AT) as the 
active component is made according to the following pro 
cedure: 1.01 g. of miconazole nitrate is suspended in 2 mL 
of 50% w/v solution of PVP (polyvinylpyrollidone) in 
MeOH producing the coating suspension of PVP and 
miconazole in a 1:1 ratio. The hard gelation or starch 
capsule, size 0, is coated by the coating suspension and then 
dried. The extent of the loading of the outer layer on a O-size 
hard capsule ranges from 110 to 216 mg. The amount of 
miconazole nitrate in this outer layer ranges from 50 to 100 
mg. 
This example illustrates the solubility of the drug in the 
coating solvent does not create a limitation on the practice 
of the invention. The coating procedure can be practiced 
with a highly soluble drug as well as a completely insoluble 
drug component or active agent. 
EXAMPLES 
Solute (active component) release from the rapidly releas 
ing compartment of the outer layer is conducted under 
following conditions: the hard gelatin capsule with the outer 
layer of the active component and excipient is placed into 10 
mL (this volume is used in order to achieve similar release 
environment for the vaginal application) of Water pH 5.0 and 
stirred at 24° C. or 37° C. Concentration of solute (PVP-II 
N-9) in the dissolution (release) medium is followed by 
monitoring absorbance of iodine at 353 nm. Absorbance is 
converted to concentration using absorptivity of iodine 
determined from the calibration measurement. FIG. 2 rep 
resents an example of PVP-I/N-9 release measured by the 
rate of iodine release from the outer layer of the capsule. 
EXAMPLE6 
Solute release from an intermediary compartment, repre 
sented by the powder formulation of the drug and excipients 
inside the capsule, is conducted under the following condi 











mg-170 mg) and disintegrant AC-DI-SOL (100-180 mg). A 
hard capsule which is packed with a mixture of PVP-I/N-9 
and AC-DI-SOL, is placed into 10 mL of water pH 5.0 and 
stirred at 24° C. to 37° C. Concentration of solute (active 
component PVP-I/N-9) in the release medium was followed 
by monitoring the absorbance of iodine at 353 nm. Absor 
bance is converted to concentration using absorptivity of 
iodine determined from the calibration measurement. FIG. 3 
is an example of PVP-I/N-9 release from a hard capsule size 
0, packed with 170 mg of PVP-I/N-9 and 170 mg of 
Ac-Di-Sol. 
EXAMPLE 7 
Solute release from the slow release inner compartment, 
represented by a multiparticulate form of PVP-I/N-9 and 
other excipients is conducted under the following condi 
tions: A hard capsule size 0 is packed with ?ller polyvi 
nylpyrrolidone (PVP) 170 mg, disintegrant Ac-Di-Sol 170 
mg and 5 pellets (3 mm diameter, 30 mg each) are dispersed 
into the powder content of the hard capsule. The pellets are 
compressed from the mixture of PVP-IlN-9 7%—70% , 
calcium phosphate or lactose 84—10%, magnesium stearate 
6%—20%, Ac-Di-SolTM 3%—0, using pressure of 600-1000 
pounds. 
A hard capsule packed With ?ller, disintegrant and ?ve 
pellets is placed into 10 mL of water pH 5.0 and stirred at 
24° C. or 37° C. Concentration of solute (active component 
PVP-I/N-9) in the release medium is followed by monitoring 
absorbance of iodine at 353 nm. Absorbance is converted to 
concentration as described in Example 3. FIG. 4 is an 
example of PVP-I/N-9 release from the slow compartment 
of a hard gelatin capsule comprised from 5 PVP-I/N-9 
pellets, dispersed into a powder containing 1'70 mg of PVP 
and 170 mg of Ac-Di-Sol. 
EXAMPLE 8 
An example of intermediate compartment delivery is set 
forth below. AO-size hard gelatin capsule was ?lled with 125 
mg of PVP-I/Nonoxynol-9 powder and 100 mg. of an 
internally crosslinked sodium carboxymethyl-cellulose 
disintegrant, USP purity, AC-DI-SOL. In this embodiment, 
the time of ?rst release of the drug into water with a pH of 
5.0 at 24° C. was 2 to 3 hours. , . 
EXAMPLE 9 
An example of inner compartment delivery is set forth 
below. A 0-size hard capsule is packed with 170 mg of a PVP 
?ller and 170 mg of AC-DI-SOLTM and ?ve pellets each 
containing 10%—84% calcium phosphate, 6%—20% magne 
sium stearate, 0%—3% AC-DI-SOL, and 7%—70% of the 
desired drug, the time of ?rst release of the drug into water 
of pH 5.0 at 24° C. was within a range of 1 to 2 hours. A 
complete release of the drug may be attained within 7 to 8 
hours. ' 
EXAMPLE 10 
Same as example 9, except that the ?ve pellets are coated 
with a coating solution to prolong the time prior of drug 
delivery from the pellets. This coating solution adopted for 
sustained release in the gastrointestinal tract may contain 
mixtures of waxes with glycerol monostearate, stearic acid, 
palrnitic acid, shellac and zein-polymers, ethylcellulose 
acrylic resins and other materials apparent to those of skill 





An example of a complete three compartment capsule is 
set forth below. A 0-size hard capsule is packed with 170 mg 
of a PVP ?ller and 170 mg of AC-DI-SOLTM and ?ve 3 mm 
pellets, each containing 10%-84% calcium phosphate, 
6%—20% magnesium stearate, 0%—3% AC-DI-SOL, and 
7%-70% of acyclovir. The intermediary compartment, rep 
resented by the powder formulation of acyclovir and excipi 
ents is introduced inside the hard capsule surrounding the 
pellet formulation. The intermediate compartment consists 
of acyclovir powder (125 mg-170 mg) and disintegrant 
AC-DI-SOLTM (100-180 mg). 
A coating solution containing acyclovir as the active 
component is made according to the general procedure 
described in Example 1; 1 mL of 50% w/v stock solution of 
CARBOWAXTM 1,450 is mixed with 3 mL of 20% w/V 
stock solution of acyclovir, producing the solution of CAR 
BOWAXTM 1,450 and acyclovir in a 10%/15% w/v ratio. 
The hard gelatin or starch capsule, size 0, is coated by the 
coating solution and then dried. The coating solution sur 
rounds the capsule wall and thus surrounds the intermediate 
drug powder compartment. The extent of the coating of the’ 
outer compartment on a O-sized starch capsule ranges from 
about 20 to 30 mg. The amount of acyclovir in this outer 
layer ranges from about 12 to 18 mg. 
EXANIPLE 12 
Same as example 11, except that the instead of acyclovir 
the capsule contains an odoriferous agent. 
EXA1VIPLE13 . 
Same as example 11, except that the instead of acyclovir 
the capsule contains Octoxynol, a spermicidal agent. The 
drug delivery system hard capsule is for vaginal delivery. 
EXAMPLE 14 
Same as example 11, except that the instead of acyclovir 
the capsule contains penicillin, an antibiotic. The drug 
delivery system hard capsule is for gastrointestinal delivery. 
EXAMPLE 15 
Peptide Capsule 
A zero size hard capsule is packed with 180 mg. of 
taurocholate, 180 mg of sodium myristate, and 0.5 mg of 
leupeptine, and 10 IU of insulin. As the inner compartment 
of the capsule, ?'te capsule contains three pellets, each 
containing 10-84% of calcium phosphate, 60-20% of mag 
nesium stearate, and insulin 40 IU. ‘ 
The outer compartment consists of two layers. The ?rst 
layer contains 20 mg. of sodium tanrocholate, 20 mg. of 
sodium myristate, 0.5 mg. of leupeptine and 3.5 mg of 
CARBOWAX 1450. After the ?rst layer is established, the 
second layer is created by dipping (or spraying) the capsule 
in an aqueous dispersion of Eudragit S100 and Eudragit NE 
30D in a 3:7 ratio. 
EXANIPLE 16 
Same as example 15, except that a 0 size hard capsule is 
packed with 180 mg of sodium taurocholate, 180 mg of 
sodium caprylate, 0.5 mg of aprotinin, calcitonin. As the 
inner compartment of the capsule, the capsule contains three 
pellets, each containing 10—84% of calcium phosphate, 
60-20% of magnesium stearate, and calcitonin. 
The outer compartment consists of two layers. The ?rst 
layer contains 20 mg of sodium caprylate, 20 mg of sodium 









After the ?rst layer is established, the second layer is 
created by dipping (or spraying) the capsule in an aqueous 
dispersion of Eudragit NE30 and Eudragit S 100 SOD in a 7:3 
ratio. The capsule is coated with a 10% cellulose acetate 
phthalate in acetone/methanol (1:1 ratio) solution. 
EXAMPLE 17 
One a Day Capsule 
A zero size hard capsule is packed with 10 mg of 
nifedipine, 200 mg of lactose, 100 mg of starch and 3 pellets. 
Each of the pellets of the inner compartment contains 10 
rag-20 mg of nifedipine, 10-84% of calcium phosphate, 
60-20% of magnesium stearate. 
The pellets are coated with a coating solution containing 
glyceryl monostearate 11% w/w, glyceryl distearate 16% 
w/w, white wax USP 3% w/w, carbon tetrachloride 65% 
w/W, PVP 2%, starch 2,8% titanium oxide 0.1%, CARBO 
WAX 1400 0.1%. 
The outer compartment is represented by 10-20 mg of 
nifedipine 6-13 mg of CARBOWAX and 12-26 mg of 
HPMC or HPC. 
EXAMPLE 18 
Sarne as Example 17, except that instead of HPMC the 
outer compartment contains PVP. 
The purpose of the above description and examples is to 
illustrate some embodiments of the present invention with 
out implying any limitation. It will be apparent to those of 
skill in the art that various modi?cations and variations may 
be made in the capsule and method of the present invention 
without departing from the spirit or scope of the invention. 
We claim: . 
1. A hard capsule drug delivery system comprising: 
a. at least one slow rate releasing compartment compris 
ing pellets or granules and at least one drug; 
b. at least one intermediate rate releasing compartment, 
said intermediate releasing compartment comprising 
powder or granules containing at least one drug; 
c. a hard capsule which houses said intermediate rate 
releasing and said slow rate releasing compartments; 
and 
d. a fast rate releasing outer layer comprising at least one 
drug and excipients, which surrounds completely said 
hard capsule. 
2. A hard capsule according to claim 1 wherein said fast 
rate releasing layer releases said drug within about one 
minute after immersion of said hard capsule into an aqueous 
medium and the release is completed in about 40 to 50 
minutes. 
3. Ahard capsule according to claim 1 wherein the release 
of said drug from said intermediate rate releasing compart 
ment occurs from about 10 minutes to about 1.5 hours after 
irmnersion of said hard capsule into an aqueous medium and 
is completed in about 4 to 5 hours. 
4. Ahard capsule according to claim 1 wherein the release 
of said drug from said slow rate releasing compartment 
occurs from about 1 to 2 hours after immersion of said hard 
capsule into an aqueous medium and is completed in about 
7 to 8 hom's. 
5. A hard capsule according to claim 1 wherein said hard 
capsule delivery system comprises a controlled release for 
mulation for a single dosage per day delivery. 
6. A hard capsule delivery system according to claim 1 
wherein said delivery system is administered orally. 
7. A hard capsule delivery system according to claim 1 
wherein said delivery system is administered vaginally. 
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8. A hard capsule according to claim 1 wherein said drug 
in said outer fast rate releasing layer is a protease inhibitor 
and said drug in said intermediate rate releasing and said 
slow rate releasing compartments is a peptide drug. 
9. A hard capsule according to claim 1 wherein said drug 
in said outer fast rate releasing layer and said intermediate 
rate releasing compartment is a protease inhibitor and said 
drug in said slow rate releasing compartment is ‘a peptide 
drug. 
10. A hard capsule of claims 8 and 9 wherein said slow 
rate releasing compartment further comprises an absorption 
enhancer. 
11. A hard capsule according to claim 1 wherein said drug 
in said outer fast rate releasing layer and said intermediate 
rate and slow rate releasing compartments is nonoxynol-9. 
12. A hard capsule according to claim 1 wherein said drug 
in said outer fast rate releasing layer and said intermediate 
rate and slow rate releasing compartments is an anti-HIV 
drug. 
13. A hard capsule according to claim 1 wherein said drug 
in said outer fast rate releasing layer and said intermediate 
rate and slow rate releasing compartments is nifedipine. 
14. A hard capsule according to claim 1 wherein said drug 
in said outer fast rate releasing layer and said intennediate 





15. Ahard capsule according to claim 1 wherein said outer 
fast rate releasing layer further comprises components 
selected from the group consisting of excipients, binders, 
plasticizers and mixtures thereof in concentration of 
l0-l2.5% by weight of said outer fast releasing layer. 
16. A hard capsule according to claim 15 wherein drug 
concentration in said outer fast rate releasing layer ranges 
from 8 to 50% by weight of said outer fast rate releasing 
layer. 
17. A hard capsule according to claim 1 wherein said 
intermediate rate releasing and said slow rate releasing 
compartments further comprise components selected from 
the group consisting of excipients, binders, plasticizers and 
mixtures thereof in concentration of 30 to 5 0% by weight of 
said intermediate rate releasing and said slow rate releasing 
compartments. 
18. A hard capsule according to claim 17 wherein said 
drug concentration in said intermediate rate releasing and 
said slow rate releasing compartments ranges from 50 to 
70% by Weight of said intermediate rate releasing and said 
slow rate releasing compartments. 
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